Leading Brazilian toiletries maker Hypermarcas looks to expand further in the OTC drug market by offering $751 million for drug firm Neo Quimica. The deal ties in with the firm's strategy to build its brand portfolio in the personal and beauty care sectors as jobs and household income grow in Brazil. The firm has made 24 takeovers since its founding in 2000. Neo Quimica, founded in 1959 and based in Goias, had gross revenue of $217.6 million over the past 12 months. According to the agreement, the Goncalves family, which controls Neo Quimica, will hold two seats on Hypermarcas' nine-member board and will form part of the company's ruling bloc
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.
